Product Data Sheet

Bromo-PEG2-C2-Boc

Cat. No.: HY-141365 CAS No.: 1381861-91-1 Molecular Formula: $C_{11}H_{21}BrO_4$ Molecular Weight: 297.19

Target: **PROTAC Linkers**

Pathway: **PROTAC**

Storage: Pure form -20°C 3 years

4°C 2 years

In solvent -80°C 6 months

> -20°C 1 month

SOLVENT & SOLUBILITY

In Vitro

DMSO: 100 mg/mL (336.49 mM; Need ultrasonic)

| Preparing Stock Solutions | Solvent Mass Concentration | 1 mg | 5 mg | 10 mg |
|------------------------------|-------------------------------|-----------|------------|------------|
| | 1 mM | 3.3649 mL | 16.8243 mL | 33.6485 mL |
| | 5 mM | 0.6730 mL | 3.3649 mL | 6.7297 mL |
| | 10 mM | 0.3365 mL | 1.6824 mL | 3.3649 mL |

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

| Description | ${\tt Bromo-PEG2-C2-Boc}\ is\ a\ {\tt PEG-based}\ {\tt PROTAC}\ linker\ that\ can\ be\ used\ in\ the\ synthesis\ of\ {\tt PROTACs}^{[1]}.$ | |
|---------------------------|--|-------------|
| IC ₅₀ & Target | PEGs | Alkyl/ether |
| In Vitro | PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | |

REFERENCES

[1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com